Clinical Trial 2022

13-giu-2022

Title	Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double- Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies
NCT Number	2021-005092-39 (EudraCT)
Conditions	atherosclerotic cardiovascular disease (ASCVD)
Interventions
Sponsor/Collaborators	NewAmsterdam Pharma B.V.
Gender	All
Age	18 years of age at Screening (Visit 1)
Phases	Phase 3
Enrollment	9000 participants
Study Type	Therapeutic confirmatory (Phase III)
Study Designs	Controlled Randomised Double blind
Start Date	12/04/2022
Completion Date	07/12/2026
Locations	Prof. Maurizio Averna, A.O.U. Policlinico P. Giaccone di Palermo
URL	https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-005092-39/IT

Title	ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
NCT Number	NCT03301506 CB8025-31731 Prot. Cb8025-31731-Re Codice Eudract: 2020-005198-29
Conditions
Interventions	Parallel Assignment
Sponsor/Collaborators	CymaBay Therapeutics, Inc.
Gender	All
Age	18 Years to 75 Years (Adult, Older Adult)
Phases
Enrollment	500 participants
Study Type	Interventional (Clinical Trial)
Study Designs	Allocation: Non-Randomized \| Intervention Model: Parallel Assignment \| Masking: None (Open Label) \| Primary Purpose: Treatment
Start Date	12/12/2017
Completion Date	01/12/2025
Locations	Sperimentatore: Prof.ssa V. Calvaruso; Centro: U.O.C. di Gastroenterologia ed Epatologia A.O.U. Policlinico P. Giaccone di Palermo; Promotore: CymaBay Therapeutics, Inc. CRO: PPD Italy s.r.l.
URL	https://clinicaltrials.gov/ct2/show/NCT03301506

Title	TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib With a 52-week Extension Phase in Patients With Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness
NCT Number	NCT05014672 GSN000350 2021-001810-13 ( EudraCT Number )
Conditions	Primary Biliary Cholangitis Liver Stiffness
Interventions	Parallel Assignment
Sponsor/Collaborators	Calliditas Therapeutics Suisse SA
Gender	All
Age	18 Years and older (Adult, Older Adult)
Phases	Phase 2 Phase 3
Enrollment	318 participants
Study Type	Interventional (Clinical Trial)
Study Designs	Allocation: Randomized \| Intervention Model: Parallel Assignment \| Intervention Model Description: Placebo-controlled 1:1:1 in double blind treatment period with 1:1 reassignment to setanaxib in extension period \| Masking: Double (Participant, Investigator)
Start Date	14/02/2022
Completion Date	15/09/2025
Locations	Sperimentatore: Dott.ssa V. Calvaruso Centro: U.O.C. di Gastroenterologia Promotore: Genkyotex Suisse SA CRO: Pharmaceutical Research Associates Italy S.r.l.
URL	https://clinicaltrials.gov/ct2/show/NCT05014672

Title	An Open-Label Extension Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
NCT Number	NCT05130450 - (EudraCT Number: 2021-003280-95)
Conditions	Familial Chylomicronemia Syndrome
Interventions	Drug: Olezarsen
Sponsor/Collaborators	Ionis Pharmaceuticals, Inc.
Gender	All
Age	18 Years and older (Adult, Older Adult)
Phases	Phase 3
Enrollment	60
Study Type	Interventional
Study Designs	Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment
Start Date	18/11/2021
Completion Date	30/04/2025
Locations	Italy UOC di Farmacia AOUP PAOLO GIACCONE - Palermo, Italy, 90127 and other 11 international study locations
URL	https://ClinicalTrials.gov/show/NCT04568434

Title	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients With Severe Hypertriglyceridemia
NCT Number	NCT05079919 - (EudraCT Number: 2021-002192-19)
Conditions	Severe Hypertriglyceridemia
Interventions	Drug: Olezarsen Drug: Placebo
Sponsor/Collaborators	Ionis Pharmaceuticals, Inc.
Gender	All
Age	18 Years and older (Adult, Older Adult)
Phases	Phase 3
Enrollment	540
Study Type	Interventional
Study Designs	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment
Start Date	25/10/2021
Completion Date	28/02/2025
Locations	Italy Ospdale E. Bassini - Milano, Italy, 20092 A.O. Policlinico Universitario P. Giaccone - Palermo, Italy, 90127 Policlinico Umberto - Roma, Italy, 00161 and other 94 international study locations
URL	https://ClinicalTrials.gov/show/NCT05079919

Title	Impact of Extra Virgin Olive Oil (EVOO) With Health Properties in Improving the Overall Health Status and Preventing Cardiovascular Risk in Metabolic Syndrome
NCT Number	NCT05282316
Conditions	Metabolic Syndrome
Interventions	Dietary Supplement: EVOO polyphenols enriched Dietary Supplement: EVOO standard
Sponsor/Collaborators	University of Palermo
Gender	All
Age	18 Years and older (Adult, Older Adult)
Phases	Phase 3
Enrollment	90
Study Type	Interventional
Study Designs	Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Double-blind placebo-controlled Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Masking Description: Same organoleptic features of the two different kind of EVOO (polyphenols enriched and standard). Primary Purpose: Prevention
Start Date	18/02/2022
Completion Date	31/12/2024
Locations	Italy Department of Internal Medicine, University Hospital of Palermo Recruiting Palermo, Italy, 90127 Contact: Aurelio Seidita, MD +390916554710 aurelio.seidita@unipa.it Contact: Maurizio Soresi, MD +390916554710 maurizio.soresi@unipa.it Sub-Investigator: Lydia Giannitrapani, MD
URL	https://ClinicalTrials.gov/show/NCT05282316

Title	Semaglutide Cardiovascular Outcomes Trial in Patients With Type 2 Diabetes
NCT Number	NCT03914326 EX9924-4473 2018-003141-42 ( Registry Identifier: European Medicines Agency (EudraCT) ) U1111-1218-5368 ( Other Identifier: World Health Organization (WHO) )
Conditions	Diabetes Mellitus, Type 2
Interventions	Parallel Assignment
Sponsor/Collaborators	Novo Nordisk A/S
Gender	All
Age	50 Years and older (Adult, Older Adult)
Phases	Phase 3
Enrollment	9642 participants
Study Type	Interventional (Clinical Trial)
Study Designs	Allocation: Randomized \| Intervention Model: Parallel Assignment \| Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) \| Masking Description: Sponsor staff involved in the clinical trial is masked according to company standard procedures
Start Date	17/06/2019
Completion Date	29/07/2024
Locations	A.O.U. Policlinico P. Giaccone di Palermo
URL	https://clinicaltrials.gov/ct2/show/NCT03914326

Title	Reparixin 1200 mg TID as add-on to SoC to Limit Disease Progression in Hospitalised Patients With COVID-19 and Other Community-Acquired Pneumonia. A Multicentre, Randomised, Double-blinded, Placebo-controlled, Phase III Trial (REPAVID-22)
NCT Number	NCT05254990
Conditions	Infectious Pneumonia Severe COVID-19
Interventions	Parallel Assignment
Sponsor/Collaborators	Dompé Farmaceutici S.p.A.
Gender	All
Age	18 Years and older (Adult, Older Adult)
Phases	Phase 3
Enrollment	526 participants
Study Type	Interventional (Clinical Trial)
Study Designs	Allocation: Randomized \| Intervention Model: Parallel Assignment \| Intervention Model Description: male and female patients >18 years, hospitalised for COVID-19, will be assigned (1:1) to receive either oral reparixin (treatment group) or matched placebo (control group) three times a day (TID) for up to 21 days. \| Masking: Triple (Participant, Care Provider, Investigator)
Start Date	06/04/2022
Completion Date	01/03/2024
Locations	Sperimentatore: Prof. N. Scichilone Centro: U.O.C. di Pneumologia
URL	https://clinicaltrials.gov/ct2/show/NCT05254990

Title	Prospective Randomized Study on the Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-myelodysplastic Syndromes, Performed Upfront or Preceded by Azacitidine or Conventional Chemotherapy According to the BM-blast Proportion
NCT Number	NCT04184505 MDS 0519 Codice Eudract: 2019-003997-25
Conditions	High-risk MDS
Interventions	Parallel Assignment
Sponsor/Collaborators	Gruppo Italiano Malattie EMatologiche dell'Adulto
Gender	All
Age	18 Years to 70 Years (Adult, Older Adult)
Phases	Phase 3
Enrollment	274 participants
Study Type	Interventional (Clinical Trial)
Study Designs	Allocation: Randomized \| Intervention Model: Parallel Assignment \| Masking: None (Open Label) \| Primary Purpose: Treatment
Start Date	27/11/2020
Completion Date	01/03/2024
Locations	Sperimentatore: Prof. S. Siragusa Centro: U.O.C. di Ematologia Sponsor: Fondazione GIMEMA Franco Mandelli Onlus
URL	https://clinicaltrials.gov/ct2/show/NCT04184505

Title	A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Italy
NCT Number	NCT05230615
Conditions	Diabetes Mellitus, Type 2
Interventions	Drug: Oral semaglutide
Sponsor/Collaborators	Novo Nordisk A/S
Gender	All
Age	age above or equal to 18 years
Phases
Enrollment	462
Study Type	Observational
Study Designs	Observational Model: Cohort Time Perspective: Prospective
Start Date	01/04/2022
Completion Date	03/11/2023
Locations	Sperimentatore: Prof. ssa Carla Giordano Centro: U.O.C. di Endocrinologia Sponsor: Novo Nordisk A/S CRO: IQVIA
URL	https://clinicaltrials.gov/ct2/show/NCT05230615

Title	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
NCT Number	NCT04568434 - (EudraCT Number: 2020-002536-67)
Conditions	Familial Chylomicronemia Syndrome
Interventions	Drug: Olezarsen Drug: Placebo
Sponsor/Collaborators	Sponsor: Ionis Pharmaceuticals, Inc. Collaborator: Akcea Therapeutics
Gender	All
Age	18 Years and older (Adult, Older Adult)
Phases	Phase 3
Enrollment	66
Study Type	Interventional
Study Designs	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment
Start Date	16/11/2020
Completion Date	31/10/2023
Locations	Italy ASST Grande Ospedale Metropolitano Niguarda - Milano, Italy, 20162 Azienda Ospedaliera Universitaria Federico II - Napoli, Italy, 80131 Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone - Palermo, Italy, 90127 Azienda Ospedaliero Universitaria Policlinico Umberto I - Roma, Italy, 00161 and other 48 international study locations
URL	https://ClinicalTrials.gov/show/NCT04568434

Title	Contribution of KIR Genes on the Genetic Predisposition to Non-Celiac Wheat Sensitivity
NCT Number	NCT05469971
Conditions	Non-celiac Wheat Sensitivity
Interventions	Genetic: KIR genotyping
Sponsor/Collaborators	Pasquale Mansueto, University of Palermo
Gender	All
Age	18 Years to 65 Years (Adult, Older Adult)
Phases
Enrollment	150 participants
Study Type	Observational
Study Designs	Observational Model: Case-Control Time Perspective: Retrospective
Start Date	01/11/2022
Completion Date	30/09/2023
Locations	Pasquale Mansueto, University of Palermo
URL	https://clinicaltrials.gov/ct2/show/NCT05469971

Title	Randomised, Open-label and Parallel Group Trial to Investigate the Effects of Oral BI 685509 Alone or in Combination With Empagliflozin on Portal Hypertension After 8 Weeks Treatment in Patients With Clinically Significant Portal Hypertension (CSPH) in Compensated Cirrhosis
NCT Number	NCT05282121 1366-0029 2021-005171-40 ( EudraCT Number )
Conditions	Liver Diseases Hypertension, Portal
Interventions	Parallel Assignment
Sponsor/Collaborators	Boehringer Ingelheim
Gender	All
Age	18 Years to 75 Years (Adult, Older Adult)
Phases	Phase 2
Enrollment	80 participants
Study Type	Interventional (Clinical Trial)
Study Designs	Allocation: Randomized \| Intervention Model: Parallel Assignment \| Masking: None (Open Label) \| Primary Purpose: Treatment
Start Date	26/05/2022
Completion Date	28/07/2023
Locations	Sperimentatore: Prof.ssa V. Calvaruso Centro: U.O.C. di Gastroenterologia
URL	https://clinicaltrials.gov/ct2/show/NCT05282121

Title	A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older
NCT Number	NCT05420961 V116-006 jRCT2071220025 ( Registry Identifier: jRCT ) 2021-006679-41 ( EudraCT Number )
Conditions	Pneumonia, Pneumococcal
Interventions	Parallel Assignment
Sponsor/Collaborators	Merck Sharp & Dohme LLC
Gender	All
Age	50 Years and older (Adult, Older Adult)
Phases	Phase 3
Enrollment	700 participants
Study Type	Interventional (Clinical Trial)
Study Designs	Allocation: Randomized \| Intervention Model: Parallel Assignment \| Masking: Double (Participant, Investigator) \| Masking Description: Cohorts 1 and 2: participants, investigator, sponsor Cohort 3: no blinding
Start Date	12/07/2022
Completion Date	18/05/2023
Locations	A.O.U. Policlinico P. Giaccone di Palermo: Claudio Costantino (MED/42), Francesco Vitale (MED/42), Carmelo Massimo Maida (MED/42), Fabio Tramuto (MED/42), Vincenzo Restivo (MED/42)
URL	https://clinicaltrials.gov/ct2/show/NCT05420961

Title	A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease
NCT Number	NCT05378529
Conditions	Atherosclerotic Cardiovascular Disease
Interventions	Other: Lp(a) Screening
Sponsor/Collaborators	Amgen
Gender	All
Age	18 Years to 85 Years (Adult, Older Adult)
Phases	Not Applicable
Enrollment	40000
Study Type	Interventional
Study Designs	Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Basic Science
Start Date	19/04/2022
Completion Date	22/05/2023
Locations	Italy Azienda Ospedaliero Universitaria di Bologna Policlinico S Orsola Malpighi - Bologna, Italy, 40138 Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia - Brescia, Italy, 25123 Azienda Ospedaliera Sant Anna e San Sebastiano - Caserta, Italy, 81100 Azienda Ospedaliera Universitaria di Ferrara Arcispedale Sant Anna - Ferrara, Italy, 44124 Ospedale Policlinico San Martino IRCCS - Genova, Italy, 16132 IRCCS Centro Cardiologico Monzino - Milano, Italy, 20138 Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda - Milano, Italy, 20162 Azienda Ospedaliera Universitaria Maggiore della Carita - Novara, Italy, 28100 Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone - Palermo, Italy, 90127 Fondazione Policlinico Tor Vergata - Roma, Italy, 00133 IRCCS Istituto Clinico Humanitas - Rozzano MI, Italy, 20089 Azienda Ospedaliera Ordine Mauriziano di Torino - Torino, Italy, 10128 and other 607 international study locations
URL	https://ClinicalTrials.gov/show/NCT05378529

Title	A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)
NCT Number	NCT04270760 20180109 2019-003688-23 ( EudraCT Number )
Conditions
Interventions	Parallel Assignment
Sponsor/Collaborators	Amgen
Gender	All
Age	18 Years to 80 Years (Adult, Older Adult)
Phases
Enrollment	700 participants
Study Type	Interventional (Clinical Trial)
Study Designs	Allocation: Randomized \| Intervention Model: Parallel Assignment \| Masking: Double (Participant, Investigator) \| Primary Purpose: Treatment
Start Date	28/07/2020
Completion Date	18/05/2023
Locations	A.O.U. Policlinico P. Giaccone di Palermo
URL	https://clinicaltrials.gov/ct2/show/NCT04270760

Title	Not-celiac Wheat Sensitivity (NCWS) in Patients With Irritable Bowel Syndrome. Randomized Double-Blind Placebo-Controlled Trial (Wheat vs Placebo) for Bio-markers Identification of NCWS and Understanding Its Pathogenetic Mechanisms.
NCT Number	NCT01762579
Conditions	Not-celiac Wheat Sensitivity
Interventions	Parallel Assignment Dietary Supplement: wheat flour Dietary Supplement: Xylose
Sponsor/Collaborators	Pasquale Mansueto, University of Palermo
Gender	All
Age	18 Years to 65 Years (Adult, Older Adult)
Phases
Enrollment	100 participants
Study Type	Interventional (Clinical Trial)
Study Designs	Allocation: Randomized \| Intervention Model: Parallel Assignment \| Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) \| Primary Purpose: Diagnostic
Start Date	01/01/2012
Completion Date	01/01/2023
Locations	Internal Medicine, University Hospital Palermo, Italy, 90100 Contact: Antonio Carroccio, PHD Contact: Pasquale Mansueto, MD Sub-Investigator: Alberto D'Alcamo, MD Sub-Investigator: Giusi Randazzo, MD Sub-Investigator: Miriam Carta, MD Sub-Investigator: Giuseppe Taormina, MD
URL	https://clinicaltrials.gov/ct2/show/NCT01762579

Elenco altri Trial approvati dal Comitato Etico Palermo 1 di cui è in corso il reperimento nelle Banche Dati

Data	TRIAL
14/06/2022	Progetto Madonie – progetto per la caratterizzazione di pazienti a rischio cardiovascolare moderato, alto e molto alto e pazienti affetti da ipercolesterolemia familiare
01/01/2022 - 31/12/2022	Treatment of High and Very high riSk dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events in Europe – a MultInatioNal ObservatIonal Study (SANTORINI)
01/01/2022 - 31/12/2022	Time-course dei livelli plasmatici di PCSK9 in pediatria
01/01/2022 - 31/12/2022	Treatment of High and Very high riSk dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events in Europe – a MultInatioNal ObservatIonal Study (SANTORINI)
06/05/2020 - 07/02/2022	Clinical characteristics and pathogenic mechanisms of anemia in Non-Celiac Wheat Sensitivity compared to Celiac Disease and Irritable Bowel Syndrome
31/12/2022	Adesione Alla Vaccinazione Anti-Papillomavirus Nelle Donne Con Accesso Allo Screening Del Tumore Della Cervice Uterina: Studio Cross-Sectional Basato Sul Modello Comportamentale Health Action Process Approach
31/12/2022	Confronto Del Rischio Di Insufficienza Renale Acuta Nei Pazienti Sottoposti Alla Terapia Di Combinazione Piperacillina Tazobactam E Vancomicina (Tzp-Van) Vs Piperacillina Tazobactam E Teicoplanina (Tzp-Tei). Prot. Concomitant
31/12/2022	Dieta Chetogenetica Ipocalorica, Normoproteica, Ipoglucidica (Vlckd) Nella Malattia Di Cushing
31/12/2022	Differenze Legate Al Sesso Nella Presentazione Clinica, Trattamento E Prognosi Dei Tumori Neuroendocrini Con Sindrome Da Carcinoide: Studio Retrospettivo Multicentrico
31/12/2022	Effetti Dell'Implementazione Del Myo-Nositolo, Citrato Di Magnesio, Citrato Di Potassio, Acido 5-Metiltetraidrofolico, Vitamina C E Vitamine Del Gruppo B Sul Controllo Metabolico E Sugli Esiti Avversi Materno-Fetali In Gravidanza Nelle Donne Con Diabete Gestazionale
31/12/2022	Effetti Dell'Implemetazione Del Myo-Inositolo Citrato Di Magnesio, Citrato Di Potassio, Acido 5 Metiltetraidrofolico, Vitamina C E Vitamine Del Gruppo B Sul Controllo Metabolico E Sugli Esiti Avversi Materno- Fetali In Gravidanza Nelle Donne Con Diabete Gestazionale
31/12/2022	Ingegnerizzazione Della Valvola Mitrale: Controllo Bio-Ispirato Della Struttura E Della Funzione, Da Cadavere, Per Migliorare Le Prestazioni In Vivo. Prot. Biomitral
31/12/2022	Integrazione Del Mioinositolo Nel Trattamento Del Diabete Mellito Gestazionale: Effetti Sul Controllo Glicemico E Sulle Complicanze Materno-Fetali
31/12/2022	Ipovitaminosi D Nei Pazienti Con Malattia Di Cushing: Prima E Dopo La Supplementazione Con Vitamina D
31/12/2022	Monitoraggio Immunologico Post-Vaccinazione Anti Covid-19 In Particolari Gruppi Di Popolazione Italiana
31/12/2022	Pioglitazione Per Il Trattamento Di Pazienti Con Steatoepatite Non Alcolica: Meta-Analisi Per Dati Individuali Da Trial Clinici
31/12/2022	Prevenzione E Management Di Covid -19 In Rsa
31/12/2022	Progetto Prevenzione Incidenti Domestici E Promozione Attivita' Fisica Nell'Anziano
31/12/2022	Real Life Experience Of Knowledge Attitudes And Acceptance Rate Of Covid-19 And Influenza Vaccine Administration In One Of The Main Vaccination Hub Of Sicilian Region, Italy At The University Hospital Of Palermo
31/12/2022	Registro Clinico Europeo Prospettico, Multicentrico, Non Interventistico, Non Comparativo Per Valutare L'Esito Clinico E La Sicurezza Del Trattamento Di Pazienti Gravemente Infetti Con Fosfomicina E.V. Prot. Fortress
31/12/2022	Sjogren Syndrome: Biomarkers, Co-Morbidities Development Of Malignant Non-Hodgkin'S Lymphoma
31/12/2022	Spi-62 Come Trattamento Per L'Ipercortisolismo Correlato A Un Tumore Surrenale Benigno Prot. Spi-62 Cl-2002 Codice Eudract: 2022-000748-32
31/12/2022	Spondiloatriti: Esperienza Monocentrica Per Valutare Efficacia E Sicurezza Delle Terapie Ad Oggi Approvate Attraverso Un Approccio Multidisciplinare Che Prevede Studio Clinico, Laboratoristico, Strumentale E Valutazione Del Rischio Cardiovascolare E Del Coinvolgimento Tramite Esame Endoscopico Gastrointestinale
31/12/2022	Stato Di Salute Orale In Soggetti Con Fragilita' Multidimensionale
31/12/2022	Studio Adattivo Di Fase Iv Randomizzato, In Aperto, Multicentrico Per Determinare La Sicurezza E L'Efficacia Di Diversi Anticorpi Monoclonali (Moabs) Contro La Sars-Cov-2 Per Il Trattamento Precoce Del Covid-19 In Pazienti Adulti Non Ospedalizzati (Studio Monet)
31/12/2022	Studio Cross Sectional Sullo Status Vaccinale E Sulle Conoscenze Delle Vaccinazioni Raccomandate In Gravidanza E Nel Post-Partum In Un Campione Rappresentativo Di Puerpere Della Provincia Di Palermo
31/12/2022	Studio Della Perturbazione Intestinale Indotta Da Antibiotici Come Fattore Terapeutico Nell'Immunita' Antitumorale
31/12/2022	Studio Dell'Effetto Apoptotico Di Estratti Di Fumo Di Sigaretta In Eritrociti Umani Isolati
31/12/2022	Studio Osservazionale Sulla Funzionalita' Respiratoria Dei Pazienti Dimessi Con Diagnosi Di Coronavirus (Covid-19) Nel Lungo Termine. Sars-Cov2 Reflow Prot. Sars-Cov2 Reflow
31/12/2022	Studio Retrospettivo Per La Caratterizzazione Del Microbiota Intestinale In Associazione A Patologie E Alla Dieta Alimentare Nella Popolazione Italiana
31/12/2022	Studio Trasversale Sui Livelli Di Lipoproteina (A) Nei Pazienti Con Anamnesi Documentata Di Malattia Cardiovascolare Aterosclerotica (Ascvd). Prot. 20210057
31/12/2022	Studio: Validazione di un questionario sul self-care nei pazienti con malattie mieloproliferative croniche philadelphianegative. Prot. Self-Care_Aipamm
31/12/2022	Trial sul campo per la valutazione dell'efficacia di un servizio di counselling attivo sull'allattamento al seno tramite il trans theoretical model
31/12/2022	Utilizzo a lungo termine dell'albumina in pazienti con cirrosi epatica. prot. real-answear
31/12/2022	Vaccinazione Anti-Influenzale E Cosomministrazioni Raccomandate Nelle Categorie A Rischio Complicanze (Campagna Vaccinale 2022 2023)
31/12/2022	Validazione di un nuovo strumento multidimensionale nell'anziano: L'Aged Care Technology Tool
19/04/2022 -22/05/2023	A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease
16/11/2020 - 31/10/2023	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
25/10/2021 - 28/02/2025	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients With Severe Hypertriglyceridemia
18/11/2021 - 30/04/2025	An Open-Label Extension Study of AKCEA-APOCIII-LRX AdministeredSubcutaneously to Patients with Familial Chylomicronemia Syndrome(FCS)(ISIS 678354-CS13)